Glioblastoma: Difference between revisions
imported>Howard C. Berkowitz No edit summary |
imported>Meg Taylor No edit summary |
||
| (5 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
{{TOC|right}} | {{TOC|right}} | ||
{{main|Glioma}} | |||
A '''glioblastoma''' or '''glioblastoma multiforme (GBM)''' is a highly invasive tumor of the [[central nervous system]], primarily of the brain, and, more specifically, the [[cerebral hemisphere]]s, [[basal ganglia]], and [[commissural pathways]].<ref>{{MeSH}}</ref> It is not curable with present methods, although recent developments have improved median survival. Onset is most common in the fifth or sixth decade of life, but certainly can appear in any adult or adolescent stage. | A '''glioblastoma''' or '''glioblastoma multiforme (GBM)''' is a highly invasive tumor of the [[central nervous system]], primarily of the brain, and, more specifically, the [[cerebral hemisphere]]s, [[basal ganglia]], and [[commissural pathways]].<ref>{{MeSH}}</ref> It is not curable with present methods, although recent developments have improved median survival. Onset is most common in the fifth or sixth decade of life, but certainly can appear in any adult or adolescent stage. | ||
| Line 6: | Line 7: | ||
There has been an overall increase in diagnoses of gliomas in the United States, but it is argued variously that there is a true increase, or that they are being diagnosed more often due to the revised classification or better [[medical imaging]].<ref>{{citation | There has been an overall increase in diagnoses of gliomas in the United States, but it is argued variously that there is a true increase, or that they are being diagnosed more often due to the revised classification or better [[medical imaging]].<ref>{{citation | ||
| Adult glioma incidence trends in the United States, 1977-2000 (abstract) | | title = Adult glioma incidence trends in the United States, 1977-2000 (abstract) | ||
| journal = Cancer | | journal = Cancer | ||
| url = http://www.medscape.com/medline/abstract/19269895 | |||
| year = 2004 | volume = 101| issue = 10 |pages =2293-9 | | year = 2004 | volume = 101| issue = 10 |pages =2293-9 | ||
| author = Hess KR; Broglio KR; Bondy ML | | author = Hess KR; Broglio KR; Bondy ML}}</ref> | ||
==Diagnosis== | ==Diagnosis== | ||
===History and physical=== | ===History and physical=== | ||
| Line 16: | Line 18: | ||
[[Magnetic resonance imaging]] is the preferred study. GBMs characteristically have low-signal intensity on T1-weighted images and high-signal intensity on T2-weighted images. With contrast, T1-weighted images typically have a central hypodensity surrounded by a thick enhancing rim of tumor. | [[Magnetic resonance imaging]] is the preferred study. GBMs characteristically have low-signal intensity on T1-weighted images and high-signal intensity on T2-weighted images. With contrast, T1-weighted images typically have a central hypodensity surrounded by a thick enhancing rim of tumor. | ||
===Histopathology=== | ===Histopathology=== | ||
It is a more [[pleomorphism|pleomorphic]] and faster-growing form of [[astrocytoma]], and is also called Grade IV astrocytoma. In addition to pleomorphism, the histopathology includes nuclear atypia, microhemorrhage, and necrosis. Margins are irregular and it is not encapsulated. | It is a more [[pleomorphism|pleomorphic]] and faster-growing form of [[astrocytoma]], and is also called Grade IV astrocytoma. In addition to pleomorphism, the histopathology includes nuclear atypia, microhemorrhage, and necrosis. Margins are irregular and it is not encapsulated. The World Health Organization classification system of 1993 helps refine these definitions. <ref>{{citation | ||
| title = The new WHO Classification of Tumors affecting the Central Nervous System | |||
| author = Stephen B. Tatter | |||
| year = 2006 | |||
| publisher = Neurosurgical Service, [[Massachusetts General Hospital]]}}</ref> | |||
==Treatment== | ==Treatment== | ||
While surgery has always been the core of treatment, prior to the use of adjuvant radiation and chemotherapy, it could only have a limited effect, as the irregular margins and infiltrating nature of the mass preclude complete removal, and indeed extensive [[debulking]]. The current standard of care begins with maximal feasible debulking, followed by radiation and chemotherapy. Excellent supportive therapy dealing with complications is essential. | While surgery has always been the core of treatment, prior to the use of adjuvant radiation and chemotherapy, it could only have a limited effect, as the irregular margins and infiltrating nature of the mass preclude complete removal, and indeed extensive [[debulking]]. The current standard of care begins with maximal feasible debulking, followed by radiation and chemotherapy. Excellent supportive therapy dealing with complications is essential. | ||
| Line 29: | Line 35: | ||
While the preferred chemotherapeutic agent is [[temozolomide]], ongoing studies also show a value for [[BCNU]]. One study with temozolomide and radiation showed median survival of 14.6 months with radiation therapy plus temozolomide and 12.1 months with radiation therapy alone.<ref>{{citation | While the preferred chemotherapeutic agent is [[temozolomide]], ongoing studies also show a value for [[BCNU]]. One study with temozolomide and radiation showed median survival of 14.6 months with radiation therapy plus temozolomide and 12.1 months with radiation therapy alone.<ref>{{citation | ||
| title = Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial | | title = Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial | ||
| journal = The Lancet Oncology | volume=10 |issue=5 | pages 459-466 | | journal = The Lancet Oncology | volume=10 |issue=5 | pages=459-466 | ||
| url = http://www.medscape.com/medline/abstract/19269895 | |||
| author = R. Stupp, M. Hegi, W. Mason, M. van den Bent, M. Taphoorn, R. Janzer, S. Ludwin, A. Allgeier, B. Fisher, K. Belanger}}</ref> Some temozolomide-treated patients have survived for 5 years. | | author = R. Stupp, M. Hegi, W. Mason, M. van den Bent, M. Taphoorn, R. Janzer, S. Ludwin, A. Allgeier, B. Fisher, K. Belanger}}</ref> Some temozolomide-treated patients have survived for 5 years. | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Latest revision as of 06:37, 28 September 2013
A glioblastoma or glioblastoma multiforme (GBM) is a highly invasive tumor of the central nervous system, primarily of the brain, and, more specifically, the cerebral hemispheres, basal ganglia, and commissural pathways.[1] It is not curable with present methods, although recent developments have improved median survival. Onset is most common in the fifth or sixth decade of life, but certainly can appear in any adult or adolescent stage.
It is termed "malignant", which usually refers to the propensity to metastasize, but, as typical of central nervous system neoplasms, does not metastasize beyond the blood-brain barrier but expands rapidly within the central nervous system. GBM is the most common and aggressive primary (i.e., not from metastasis) brain tumor.
There has been an overall increase in diagnoses of gliomas in the United States, but it is argued variously that there is a true increase, or that they are being diagnosed more often due to the revised classification or better medical imaging.[2]
Diagnosis
History and physical
Symptoms are nonspecific, including headache, seizures, cognitive changes and focal neurologic signs.
Imaging
Magnetic resonance imaging is the preferred study. GBMs characteristically have low-signal intensity on T1-weighted images and high-signal intensity on T2-weighted images. With contrast, T1-weighted images typically have a central hypodensity surrounded by a thick enhancing rim of tumor.
Histopathology
It is a more pleomorphic and faster-growing form of astrocytoma, and is also called Grade IV astrocytoma. In addition to pleomorphism, the histopathology includes nuclear atypia, microhemorrhage, and necrosis. Margins are irregular and it is not encapsulated. The World Health Organization classification system of 1993 helps refine these definitions. [3]
Treatment
While surgery has always been the core of treatment, prior to the use of adjuvant radiation and chemotherapy, it could only have a limited effect, as the irregular margins and infiltrating nature of the mass preclude complete removal, and indeed extensive debulking. The current standard of care begins with maximal feasible debulking, followed by radiation and chemotherapy. Excellent supportive therapy dealing with complications is essential.
Techniques of radiation therapy continue to evolve. The standard of care is fractionated electron beam radiotherapy, but methods being investigated include brachytherapy with implanted 131iodine seeds, [4]
While the preferred chemotherapeutic agent is temozolomide, ongoing studies also show a value for BCNU. One study with temozolomide and radiation showed median survival of 14.6 months with radiation therapy plus temozolomide and 12.1 months with radiation therapy alone.[5] Some temozolomide-treated patients have survived for 5 years.
References
- ↑ Anonymous (2024), Glioblastoma (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Hess KR; Broglio KR; Bondy ML (2004), "Adult glioma incidence trends in the United States, 1977-2000 (abstract)", Cancer 101 (10): 2293-9
- ↑ Stephen B. Tatter (2006), The new WHO Classification of Tumors affecting the Central Nervous System, Neurosurgical Service, Massachusetts General Hospital
- ↑ Salah Uddin and Tambi Jarmi (19 April 2010), "Glioblastoma Multiforme: Treatment & Medication", eMedicine
- ↑ R. Stupp, M. Hegi, W. Mason, M. van den Bent, M. Taphoorn, R. Janzer, S. Ludwin, A. Allgeier, B. Fisher, K. Belanger, "Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial", The Lancet Oncology 10 (5): 459-466